Navigation Links
Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
Date:1/5/2011

SAN DIEGO, Jan. 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the United States Patent and Trademark Office has issued U.S. Patent 7,863,249 which covers additional dosage forms of fidaxomicin. This patent further strengthens Optimer's patent protection for fidaxomicin. The newly issued patent and a previously issued patent encompassing fidaxomicin are both orange book listable.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"The issuance of this patent is part of our intellectual property strategy to protect fidaxomicin in all methods and dosages for treating patients with Clostridium difficile infection," said Pedro Lichtinger, President and CEO of Optimer.  

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  Most importantly, fidaxomicin was statistically superior to vancomycin in global cure and in reducing recurrences of CDI by up to 47%. Optimer has filed marketing applications in the U.S. and the EU for fidaxomicin for the treatment of CDI and for the prevention of recurrences.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin).  Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  The Company has submitted an NDA to the FDA, and filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... IRVINE, Calif. , March 22, 2017 /PRNewswire/ ... Free Injection System has received an Innovative Technology ... member-driven health care company in the country. The ... J-Tip by hospital representatives with expertise in this ... councils.  Vizient reserves Innovative Technology contracts for technologies ...
(Date:3/22/2017)... MAPLE GROVE, Minn. , March 22, 2017   ... of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and ... (clomipramine hydrochloride) Capsules USP. The clomipramine ... for the 12 months ending December 2016, according to IMS ... ...
(Date:3/22/2017)... March 22, 2017 NetworkNewsWire Editorial Coverage  ... Deciphering ... differing statements by White House officials. Federal laws are at ... for medical and/or recreational use, and businesses like SinglePoint, Inc. ... (NASDAQ: CRBP), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Science, Inc. ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... In recognition of ... media enterprise focused on cancer patients, cancer centers and advocacy groups, and MJH ... educational video series, “No Ifs, Ands, or Butts,” that focuses on Colorectal Cancer ...
(Date:3/22/2017)... SC (PRWEB) , ... March 22, 2017 , ... Drs. ... expanding their patient base to accept new patients in need of skilled pediatric ... experience, India Hook Dental Care offers pediatric patients routine treatments, including cavities, sealants and ...
(Date:3/22/2017)... Park Ridge, NJ (PRWEB) , ... March 22, ... ... financial planning firm that serves communities throughout north Jersey and the New York ... Bergen County to provide regional support for homeless families. , At present, more ...
(Date:3/22/2017)... ... March 22, 2017 , ... Schneider Insurance and Financial, a southern Montana firm ... Yellowstone Valley region, is launching a charity event aimed at raising local support for ... of Montana State, and is home to a broad variety of animals from all ...
(Date:3/22/2017)... ... , ... The Senior Citizens League (TSCL) is calling on Congressional leadership ... debt — including the debt held by the Social Security Trust Fund. “Congressional ... letter to House and Senate budget leaders. “In prior debates to lift the ...
Breaking Medicine News(10 mins):